Abstract
Introductionthis study aimed to evaluate the effectiveness of botulinum toxin A (BoNT-A) injection in hemiparetic patients with chronic spasticity in the upper limb resulting from stroke or traumatic brain injury.Methodswe conducted a retrospective study including 45 patients seen, in our department of Physical Medicine and Rehabilitation, between January 2014 and December 2016. All patients received an injection of BoNT-A (Dysport, 100 U/ml). Affected upper-extremity muscles could be injected as per the investigator’s discretion to a maximum total dose of 1000 U. We evaluated muscle tone using Modified Ashworth Scale (MAS). Functional disability was assessed using Modified Frenchay Scale (MFS), Nine Hole Peg Test (NHPT) and Barthel Index (BI). Quality of life (QoL) was assessed using the 36-Item Short Form Health Survey (SF-36). The achievement of treatment goal was assessed by the Goal Attainment Scaling (GAS).Resultspatients decreased their MAS score over the first and the third months (p<0.05). MFS showed improvement at 1 month after injection with a median change from baseline of 8 (range: 1-16; p<0.001). The change from baseline ranged from 0 to 5 points for NHPT at 1 month after injection (p< 0.001). This functional improvement was maintained to 3 months. Improvements in Barthel Index was observed at 3 months with a median change from baseline of 5 points (range 0-15; p<0.001). The mean change from baseline of SF-36 score was 4.77 ± 3.39 (p<0.001). The mean GAS T-score was 47.04 ±7.78 (median 50, IQR 7.7), giving a mean (SD) change from baseline of 25.36 ± 8.46 (95% CI 22.82 to 27.90; p <0.001). Binary logistic regression was used to identify the independent factors predicting a favorable functional outcome of Bon-T treatment. It showed that neglect was independent predictive factor treatment failure (p=0.009, OR=3.2) while previous injection of BoNT-A was an independent predictive factors of treatment success (p=0.009, OR=0.3).Conclusionour study showed a good response to BoNT-A injection delivered in the management of chronic upper limb spasticity resulting from stroke or traumatic brain injury. It demonstrated its outcome in improving muscle tone, function and QoL. It also showed that the majority of patients achieved their goal as defined at the start of the treatment, mainly for patients who received previous injection of BoNT-A.
Highlights
Upper limb spasticity may cause deformity, pain and reduced function [1]
This current study aimed to evaluate, with a person-centred measure of outcome, the effectiveness of botulinum toxin A (BoNT-A) injection, in the active function, in hemiparetic patients with disabling spasticity in the upper limb resulting from chronic stroke or traumatic brain injury, and to identify baseline factors that predict favorable functional outcome of this treatment
Characteristics of participants: this study included 45 patients. They were referred from the neurological service (68.9%), the intensive care unit (ICU) (15.6%), and the orthopedic service (15.6%)
Summary
Upper limb spasticity may cause deformity, pain and reduced function [1]. The treatments of this spasticity include oral antispastic drugs, botulinum toxin and surgical treatments as selective neurotomy and orthopedic surgery [1]. The botulinum toxin is increasingly used to treat spasticity due to stroke or traumatic brain injury (TBI) This treatment has been widely shown to reduce muscle tone [2] and improve basic upper limb activities such as hand hygiene and facilitation of dressing [3]. Despite the large debate in the literature regarding the effectiveness of botulinum toxin in improving active function, very few studies have sought to identify factors predicting a favorable functional outcome of this treatment in hemiparetic patients This current study aimed to evaluate, with a person-centred measure of outcome, the effectiveness of BoNT-A injection, in the active function, in hemiparetic patients with disabling spasticity in the upper limb resulting from chronic stroke or traumatic brain injury, and to identify baseline factors that predict favorable functional outcome of this treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
